Navigation Links
Phase 1 ALS trial is first to test antisense treatment of neurodegenerative disease
Date:4/3/2013

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis (ALS) blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease may be a first step towards a new era in the treatment of such disorders. Investigators from Massachusetts General Hospital (MGH) and Washington University School of Medicine report that infusion of an antisense oligonucleotide against SOD1, the first gene to be associated with familial ALS, had no serious adverse effects and the drug was successfully distributed thoughout the central nervous system.

"This therapy directly targets the cause of this form of ALS a mutation in SOD1, which was originally discovered here at the MGH by my mentor Robert Brown," says Merit Cudkowicz, MD, chief of Neurology at MGH and senior author of the report in Lancet Neurology, which has been released online. "It's very exciting that we have reached a stage when we can start clinical trials against this type of ALS."

ALS causes the death of motor neurons in the brain and spinal cord, stopping transmission of neural signals to nerve fibers and leading to weakness, paralysis and usually death from respiratory failure. Only 10 percent of ALS cases are inherited, and mutations in SOD1 which produce an aberrant, toxic form of the protein account for about 20 percent of familial cases. Although that first SOD1 mutation was identified 20 years ago by the team lead by Brown who is now professor and chief of Neurology at the University of Massachusetts Medical School a technology that directly addresses such mutations became available only recently.

The current study, the first author of which is Timothy Miller, MD, PhD, of Washington University, used what are called antisense oligonucleotides small, single-stranded DNA or RNA molecules that prevent production of a protein by binding to its messenger RNA. While antisense medications hav
'/>"/>

Contact: Mike Morrison
mdmorrison@partners.org
617-724-6425
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... (PRWEB) May 25, 2015 A recent report ... states 1,000 persons have died as a direct result of ... This marks a 33% rise in overdose deaths attributed to ... Baker, “This issue doesn’t care about geography. This issue doesn’t ... issue doesn’t care about class.” As the state of Mass. ...
(Date:5/25/2015)... 2015 ProDrop Light Show allows users ... light backdrops with a click of a mouse. Users have full ... all within Final Cut Pro X. , ProDrop Light Show gives ... zones, kaleidoscope and much more leaving infinite possibilities all within Final ... zones and text presets, users can apply their very own media ...
(Date:5/25/2015)... Americas announces major investment in new technology and personnel ... Medical Answering Service customers. Through a combination of ... provides a seamless transition between a health care provider’s ... patient satisfaction. , Tunstall is pleased to ... expanded facilities and the latest telecommunication software and hardware ...
(Date:5/24/2015)... (PRWEB) May 25, 2015 Pacific Prime has announced ... part report looking at the cost of individual international health ... Article 2 looks at the cost of health insurance in six ... Focusing on, Hong Kong , ... the UAE , the UK , ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 For people ... and Chinese Enterokinase Industry, 2009-2019 Market Research Report would ... is an exhaustive study on the present market scenario ... insight into the growing Chinese market of this industry. ... the overall status of the manufacturers in this industry. ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4
... Choices ( http://www.nhs.uk ), the,digital ,front door, to the ... to see both the physical and financial cost of ... information, the interactive calculator,( http://www.nhs.uk/Tools/Pages/Smoking.aspx ) enables users to ... up how much you could save over,one to ten ...
... 11 In this 90 minute episode, Dr. Drew,reunites several ... they left treatment. Drew reveals who has relapsed, who has ... is comprised of,recovering addicts and fans of the show, will ... happened over the season., (Photos: ...
... suggests eating foods such as whole grains cuts risk ... -- Increased consumption of magnesium-rich foods such as whole ... which occurs when blood flow to the brain is ... the Karolinska Institute in Stockholm analyzed the diets and ...
... ALLEGAN, Mich., March 11 Perrigo Company,(Nasdaq: ... final approval,from the U.S. Food and Drug Administration (FDA) ... Foam, 0.05%., The product is a topical corticosteroid ... the scalp. Sales for the brand, Olux(R),Foam, 0.05%, were ...
... Verathon(R) is pleased to,announce a new Small Child ... instrument with patent-pending NeuralHarmonics(TM),Technology. Small Child Mode enables ... children weighing less than 60 pounds and,standing less ... used for adult,patients. This enhanced BladderScan(R) BVI 9400 ...
... . , Malignant tumors have usually lost their ... apoptosis. Therefore, tumors are often resistant to chemotherapy or ... cells to commit suicide. , This resistance to ... numerous molecular switches regulating the self-destruction process. This is ...
Cached Medicine News:Health News:Magnesium May Lower Risk for Some Strokes in Male Smokers 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 3Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 2Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 3Health News:Paradigm shift: Switch for programmed cell death promotes spread of glioblastoma 2
(Date:5/21/2015)... Research and Markets ( ... "North American Active Wound Care Market by ... & Ulcer), by End-User (In-Patient, & Out-Paient) - ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North ... grow at a CAGR of 3.1% from 2014 ...
(Date:5/21/2015)... REDWOOD CITY, Calif. , May 21, 2015  Cardica, ... 20, 2015, new employee Greg Watson , the company,s ... 400,000 shares of the company,s common stock, at a per ... May 20, 2015. The stock option was granted pursuant to ... board of directors in May 2015 under Rule 5653(c)(4) of ...
(Date:5/21/2015)... CAMBRIDGE, England , May 21, ... zur Bekämpfung von Arzneimittelfälschungen - Zwecks ... eines Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, ... Pilotsysteme betrieben werden.  Wählen Sie ein ... Bei der Richtlinie zur Bekämpfung von ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Technology advances have had a profound effect on ... a constantly evolving communication environment, companies need to continuously ... It is challenging, however, to gauge the effectiveness of ... of today,s internal and external communication options. ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the 2011 Credit Suisse Annual ... live presentation takes place on Wednesday, November 9, 2011 at ... 1:00 p.m. Pacific Time.  The presentation will be webcast and ...
Cached Medicine Technology:Internal and External Communication Insights: Effective Approaches for Reaching Clients and Co-Workers 2
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... catheter or instrument introduction. The dual ... peeled away and removed. The maximum ... to be introduced should be measured ... sheath. Supplied sterile in peel-open packages. ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: